Novelix Pharmaceuticals Limited (formerly Trimurthi Limited) announced significant corporate developments following its Board meeting held on January 19, 2026. The company successfully allotted 400,000 equity shares upon warrant conversion and made a key management appointment.

Equity Share Allotment Details

The Board approved the allotment of 400,000 equity shares with a face value of ₹10.00 each at an issue price of ₹20.00 per share, including a premium of ₹10.00 per share. These shares were issued upon conversion of warrants by non-promoter category holders who paid the remaining 75% of the issue price, amounting to ₹15.00 per warrant.

Strategic Investor Allocation

Three strategic investors participated in the warrant conversion, with the allocation distributed among non-promoter category investors:

Impact on Share Capital

Following this allotment, the company's paid-up equity capital increased substantially. The capital structure expanded from ₹172.15 crores consisting of 17,215,000 equity shares to ₹176.15 crores comprising 17,615,000 equity shares of ₹10.00 each.

Warrant Conversion Background

These warrants originated from 15,000,000 warrants allotted on January 10, 2025, on a preferential basis. The original allotment followed a special resolution passed by shareholders at an Extra-Ordinary General Meeting held on November 18, 2024, with in-principle approval received from BSE Limited on December 31, 2024. The company noted that 7,265,000 warrants had already been converted previously.

Management Appointment

The Board also approved the appointment of Mr. Gnana Prakash Gattu (DIN: 00517921), Director of the Company, as Nodal Officer under the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016. This appointment ensures compliance with regulatory requirements for investor protection and fund management.

The Board meeting commenced at 5:00 PM at the company's registered office in Hyderabad and concluded at 5:30 PM with a vote of thanks.

Novelix Pharmaceuticals Limited has officially announced the appointment of Ms. Sridevi Belide as Non-Executive Non-Independent Director, marking a significant addition to the company's board composition. The appointment was formally approved by shareholders during an Extraordinary General Meeting held on January 9, 2026, with the effective date of appointment being October 23, 2025.

Director Profile and Qualifications

Ms. Sridevi Belide brings substantial healthcare expertise to the board, holding a Bachelor of Medicine and Bachelor of Surgery (MBBS) degree. Her medical professional background positions her to contribute strategic insights in healthcare management, quality standards, and corporate governance areas that align with the pharmaceutical company's operations.

Appointment Details

The key details of the directorial appointment are outlined below:

Regulatory Compliance

The appointment has been made in accordance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has confirmed that Ms. Belide is not debarred from holding the office of Director by any SEBI order or other regulatory authority, ensuring full compliance with BSE circular requirements.

Board Composition and Relationships

Ms. Belide belongs to the promoter group of the company but maintains no familial relationships with existing directors on the board. This appointment strengthens the company's board structure while maintaining appropriate governance standards. The company has provided comprehensive disclosure as required under SEBI regulations and relevant circulars.

Company Background

Novelix Pharmaceuticals Limited, formerly known as Trimurthi Limited, operates under CIN L67120TG1994PLC018956 and trades on BSE with scrip code 536565. The company is headquartered in Hyderabad, Telangana, and continues to expand its leadership team to support its pharmaceutical operations and strategic objectives.